The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended not to grant marketing authorisation for Ipsen’s investigational palovarotene as a treatment for fibrodysplasia ossificans progressiva (FOP). The company says it will be requesting a re-examination of the CHMP opinion, based on scientific data available from the existing […]
Menu ≡ ╳ 
